MedTrace Logo

Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension

NCT04104490 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 79

Last updated 2022-10-27

No results posted yet for this study

Summary

Pulmonary arterial hypertension (PAH) is fatal with right heart failure due to raised pulmonary vascular pressure. Gut dysbiosis was identified in animals with pulmonary hypertension. Deidentified human samples will be tested for gut dysbiosis in PAH, circulating bacterial metabolites and markers of inflammation and gut leakiness. The gut microbiome and circulating metabolites, markers of inflammation and gut leakiness of PAH patients and healthy subjects will be compared in deidentified fecal samples and blood.

Conditions

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Mayo Clinic

    collaborator OTHER

  • Federal University of Health Science of Porto Alegre

    collaborator OTHER

  • University of Florida

    lead OTHER

Principal Investigators

  • Mohan Raizada · University of Florida

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-06
Primary Completion
2020-06-30
Completion
2021-12-31

Countries

  • United States
  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04104490 on ClinicalTrials.gov